Research on the specific extract of Orthosiphon stamineus, which contains the key compound rosmarinic acid, shows strong hepatoprotective (liver-protecting) effects. Rosmarinic acid helps neutralise harmful free radicals that are produced during chemotherapy, preventing oxidative damage to liver cells. Experimental and clinical studies have demonstrated that supplementation with Orthosiphon extract can reduce liver enzyme elevations—an indicator of liver stress—helping the liver function more efficiently during treatment.

​Chemotherapy can increase oxidative and inflammatory stress within blood vessels, which contributes to vascular stiffness and fatigue. Rosmarinic acid and the synergistic flavones (such as sinensetin and eupatorine) found in Nuvastatic help improve endothelial function and reduce vascular oxidative stress, thereby supporting healthy blood flow and protecting the heart. This may translate to better stamina and less chemotherapy-related fatigue.

 The kidneys play an essential role in filtering toxins, including chemotherapy metabolites. Nuvastatic has been clinically shown to reduce oxidative stress, as reflected by a significant reduction in urinary F2-isoprostanes, which are biomarkers of free radical-induced lipid damage. By lowering these oxidative stress markers, Nuvastatic supports kidney integrity, reduces inflammation in kidney tissues, and helps maintain normal renal function throughout chemotherapy.

In a human clinical study, Nuvastatic supplementation resulted in a marked reduction in urinary F2-isoprostanes, confirming its systemic antioxidant effect. This means that Nuvastatic not only works locally in the liver or kidneys but also helps protect the entire body from oxidative damage caused by chemotherapy.